Gastrointestinal functional bowel disorders: new therapies

Area of Science:

• Gastroenterology
• Neurogastroenterology
• Pharmacology

Background:

• Functional gastrointestinal disorders (FGIDs) are prevalent conditions.
• Current treatments primarily manage symptoms like altered bowel habits.
• There is a need for therapies addressing underlying pathophysiology.

Purpose of the Study:

• To review emerging therapeutic strategies for FGIDs.
• To highlight novel drug targets in nerve-gut communication.
• To discuss agents for upper gut dysmotility and visceral pain.

Main Methods:

• Literature review of current and investigational FGID therapies.
• Focus on agents modulating nerve-gut signaling pathways.
• Identification of specific molecular targets.

Main Results:

• Serotonin 5-HT3 antagonists and 5-HT4 agonists show clinical trial activity.
• Motilin and cholecystokinin A receptors are promising targets for upper gut dysmotility.
• Tachykinin, calcitonin gene-related peptide, and glutamate antagonists are key candidates for visceral pain.

Conclusions:

• New FGID therapies are shifting focus to underlying nerve-gut dysfunction.
• Targeting specific receptors offers potential for more effective treatments.
• Pharmacological advancements hold promise for managing complex FGID symptoms.